Hyndman Matthew Eric, Bivalacqua Trinity J, Mettee Lynda Z, Su Li-Ming, Trock Bruce J, Pavlovich Christian P
Department of Surgery, Division of Urology, Southern Alberta Institute of Urology, University of Calgary, Calgary, AB;
James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD;
Can Urol Assoc J. 2015 Nov-Dec;9(11-12):414-9. doi: 10.5489/cuaj.3169. Epub 2015 Nov 9.
This is a report on urinary function results from a randomized trial of nightly versus on-demand sildenafil after nerve-sparing radical prostatectomy (RP), a secondary objective. We analyzed the effects of these sildenafil administration schemes on urinary health-related quality of life after RP.
In total, 100 potent men were equally randomized to nightly and on-demand sildenafil 50 mg after minimally-invasive RP for 1 year. Health-related quality of life questionnaires were administered at various postoperative intervals. Urinary function was assessed using appropriate expanded prostate cancer index composite (EPIC) subscales. Analyses of covariance and linear mixed-effects modeling were used to compare the effects of treatment over time on urinary recovery, controlling for age, nerve-sparing score, and time from surgery.
The nightly (n = 50) and on-demand (n = 50) sildenafil groups were well-matched at baseline. Nightly sildenafil patients had worse EPIC urinary bother and urinary irritative/obstructive subscale scores at 3 and 6 months after RP, even after controlling for multiple variables. On mixed-model analyses, the differences between groups for these EPIC subscales (4.9 and 2.5, respectively) were greater than documented thresholds for clinical significance. Increasing nerve-sparing score was associated with improvements in EPIC urinary summary, bother, incontinence, and function scores; time from surgery was associated with improvements in all EPIC urinary health-related quality of life subscales.
In this specific population and drug dose, we found that on-demand short-acting phosphodiesterase-5 inhibitor (PDE5i) dosing may be more effective after RP to maximize early urinary health-related quality of life. In preoperatively potent men, nightly sildenafil 50 mg impaired urinary health-related quality of life more than on-demand use in the early months after nerve-sparing RP, independent of effects on urinary continence.
这是一项关于保留神经的根治性前列腺切除术(RP)后每晚服用与按需服用西地那非的随机试验的尿功能结果报告,这是一个次要目标。我们分析了这些西地那非给药方案对RP后与尿健康相关的生活质量的影响。
总共100名性功能正常的男性在接受微创RP后被平均随机分为每晚服用和按需服用50毫克西地那非两组,为期1年。在术后不同时间间隔进行与健康相关的生活质量问卷调查。使用适当扩展的前列腺癌指数综合(EPIC)子量表评估尿功能。采用协方差分析和线性混合效应模型来比较治疗随时间对尿恢复的影响,并控制年龄、神经保留评分和手术时间。
每晚服用(n = 50)和按需服用(n = 50)西地那非组在基线时匹配良好。即使在控制多个变量后,每晚服用西地那非的患者在RP后3个月和6个月时的EPIC尿困扰和尿刺激性/梗阻性子量表评分更差。在混合模型分析中,这些EPIC子量表的组间差异(分别为4.9和2.5)大于已记录的临床意义阈值。神经保留评分增加与EPIC尿综合、困扰、尿失禁和功能评分的改善相关;手术时间与所有EPIC尿健康相关生活质量子量表的改善相关。
在这个特定人群和药物剂量中,我们发现按需服用短效磷酸二酯酶-5抑制剂(PDE5i)在RP后可能更有效,以最大限度地提高早期与尿健康相关的生活质量。在术前性功能正常的男性中,保留神经的RP后早期,每晚服用50毫克西地那非比按需服用对与尿健康相关的生活质量损害更大,且与对尿失禁的影响无关。